Allena Pharmaceuticals, Inc. Capital Stock Change

Capital Stock Change of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital Stock Change growth rates and interactive chart.


Highlights and Quick Summary

  • Capital Stock Change for the quarter ending March 31, 2022 was $3.94 Million (a -110.14% decrease compared to previous quarter)
  • Year-over-year quarterly Capital Stock Change increased by 123.33%
  • Annual Capital Stock Change for 2021 was $18 Thousand (a -73.91% decrease from previous year)
  • Annual Capital Stock Change for 2020 was $69 Thousand (a -38.39% decrease from previous year)
  • Annual Capital Stock Change for 2019 was $112 Thousand (a -182.35% decrease from previous year)
  • Twelve month Capital Stock Change ending March 31, 2022 was $-7.74 Million (a -43105.56% decrease compared to previous quarter)
  • Twelve month trailing Capital Stock Change increased by 3639.61% year-over-year
Trailing Capital Stock Change for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-7.74 Million $18 Thousand $18.5 Million $-207 Thousand
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital Stock Change of Allena Pharmaceuticals, Inc.

Most recent Capital Stock Changeof ALNA including historical data for past 10 years.

Interactive Chart of Capital Stock Change of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Capital Stock Change for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $3.94
2021 $-38.88 $25.43 $1.77 $11.7 $0.02
2020 $-20.41 $6.74 $13.74 $0.01 $0.07
2019 $-9.52 $-0.0 $9.62 $0.01 $0.11
2018 $-0.04 $0.01 $-0.11 $0.0 $-0.14
2017 $67.22 $0.0 $0.0 $0.0 $67.23
2016 $0.02 $0.02
2015 $52.79

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.